André the Giant

Lore & Background

André René Roussimoff was born on 19 May 1946 in Coulommiers, Seine-et-Marne, to Bulgarian and Polish immigrants. At birth he weighed 13 lb (6 kg) and displayed symptoms of gigantism as a child. By age 12 he stood 191 cm (6 ft 3 in). He left school at 14, worked on his father's farm, and later trained in woodworking and factory work before moving to Paris at 18 to learn professional wrestling. He began his career in 1964 or 1965, wrestling in France, and made his TV debut in 1966. He relocated to North America in 1971, and from 1973 to the mid-1980s was booked by WWWF promoter Vincent J. McMahon as a roving special attraction, wrestling across the United States and in Japan. During the 1980s wrestling boom, he became a mainstay of the WWF, feuding with Hulk Hogan.

Reader's Guide

André the Giant's significance lies in his unprecedented size and global appeal, which made him a central figure in professional wrestling's expansion into mainstream pop culture. His undefeated streak in the WWF, though broken at WrestleMania III, was a key narrative device. His sole major world heavyweight championship win in 1988 marked a career highlight. Outside wrestling, his role as Fezzik in The Princess Bride (1987) cemented his status as a pop culture icon. After his death, he became the inaugural inductee into the WWF Hall of Fame, and his WrestleMania III match was later inducted into the Immortal Moments category in 2026. He was also a charter member of the Wrestling Observer Newsletter Hall of Fame and the Professional Wrestling Hall of Fame, which described him as 'one of the most recognizable figures in the world both as a professional wrestler and as a pop culture icon.' His legacy endures as a symbol of wrestling's global reach and the enduring appeal of larger-than-life characters.

Did You Know?

• André the Giant was born weighing 13 lb (6 kg).
• He was raised Catholic and his childhood nickname was Dédé.
• He was the inaugural inductee into the WWF Hall of Fame after his death.
• He appeared as Fezzik in the 1987 film The Princess Bride.

The Condition That Made a Legend

André the Giant's extraordinary stature was not simply a matter of being tall; it was the product of a rare medical condition known as gigantism. This disorder is defined by excessive growth that pushes a person's height at least three standard deviations above the population average, a threshold that places them in an extreme statistical outlier category. The root cause lies in the body's overproduction of growth hormone during the critical window of childhood, before the growth plates fuse—typically a process that completes soon after puberty. In the vast majority of cases, this hormonal overdrive is triggered by abnormal tumor growths, called adenomas, developing on the anterior pituitary gland. The physical consequences of carrying such a massive frame are severe. The relentless strain of maintaining an oversized, heavy body places extraordinary demands on both the skeletal and circulatory systems, leading to a cascade of health complications involving the bones and the heart. It is a condition that distinguishes itself from acromegaly, its adult counterpart, which instead produces enlargement concentrated in the extremities and face rather than overall height.

The Hormonal Machinery

Behind André the Giant's towering frame lay a complex interplay of hormones and cellular pathways. Growth hormone and insulin-like growth factor-I are the two primary substances identified as driving growth plate formation and bone elongation, though their precise mechanisms remain only partially understood. These two molecules are implicated across virtually every stage of human development—embryonic, prenatal, and postnatal. The receptor gene for IGF has shown particular influence during prenatal development, while GH receptor genes are known to drive overall growth through multiple pathways. Growth hormone acts as an upstream precursor to IGF-I, yet each maintains an independent role within hormonal cascades before ultimately converging to produce a joint effect on skeletal growth. In cases of gigantism, the excess GH is virtually always attributable to pituitary adenomas, which may simultaneously trigger overproduction of growth hormone-releasing hormone, the hypothalamic precursor. The typical age at which excessive growth symptoms first manifest hovers around thirteen years, though the precise onset varies by individual and gender. Pediatric patients may also develop hypertension as a secondary complication of the hyper-secretion.

Tracing the Genetic Thread

Pinpointing a single genetic cause for gigantism has proven remarkably elusive, and the condition remains the primary example of a group of growth hormone hyper-secretion disorders that medicine has yet to fully unravel. That said, several genetic associations have emerged. Pediatric patients have shown duplications of genes on the Xq26 chromosomal region, typically with symptom onset before the age of five, suggesting a possible linkage between those duplications and the disorder. More broadly, mutations in the AIP gene—classified as both a tumor suppressor and a pituitary adenoma disposition gene—have been identified in roughly twenty-nine percent of patients. Two specific AIP mutations have been flagged as capable of inducing pituitary adenomas early in life, a hallmark of the condition. A wider constellation of genetic disorders, including multiple endocrine neoplasia types one and four, McCune-Albright syndrome, Carney complex, and X-linked acrogigantism, have also been connected to gigantism. Yet over half of all cases resist any genetic explanation, underscoring the disorder's complexity. Diagnostically, a single normal GH reading cannot rule out hyper-secretion due to natural diurnal fluctuation, whereas a consistently elevated IGF-1 level—unaffected by such variation—serves as a far more reliable indicator.

Fighting the Growth

Treating gigantism remains a challenge riddled with criticism, and no single intervention has been universally accepted as ideal. Both surgical approaches and pharmaceutical regimens have been employed, each with limitations. Among the drugs that have drawn the most attention is pegvisomant, which works by reducing circulating levels of IGF-I. In pediatric patients, this reduction can meaningfully curb the abnormally high growth rates that characterize the condition. Pegvisomant has emerged as a powerful alternative to somatostatin analogues—the standard pharmacological treatment for acromegaly—particularly when drug therapy is paired with radiation. Finding the optimal dosage, however, is critical; too much can suppress normal body growth, so clinicians rely on careful titration to calibrate administration. A random blood sample showing markedly elevated GH is sufficient to confirm hyper-secretion, and a high-normal GH reading that fails to suppress after glucose administration also meets the diagnostic threshold. IGF-1 testing, free from diurnal variation, provides a consistently elevated signal in affected patients, and a single normal IGF-1 value can reliably exclude the condition. Despite these tools, the disorder's multifactorial nature means treatment must be tailored case by case, balancing the urgency of halting pathological growth against the risk of stunting healthy development.

Gallery